UROKINASE-SPECIFIC INHIBITORS AS ANTI-METASTATIC AGENTS

尿激酶样纤溶酶原激活剂（uPA）与组织中的 在诸如肿瘤转移、伤口愈合和创伤愈合的过程中的重构， 胚胎发育 已经开发了uPA的特异性抑制剂 其将在小鼠中作为实验性转移的抑制剂进行测定 黑素瘤模型系统。 确认uPA之间的相关性 将寻求化合物的抑制和抗转移性质， 以及将抑制剂的结构特征与它们的 体内功效 确认疗效的最终结果 作为抗转移剂测试的药物预期是 鉴定将用于所有治疗的一种或多种治疗剂， 确诊的人类实体瘤病例， 转移

Urokinase-like plasminogen activator (uPA) has been implicated in tissue remodeling during such processes as tumor metastasis, wound healing and embryological development. Specific inhibitors of uPA have been developed which will be assayed as inhibitors of experimental metastasis in a mouse melanoma model system. Confirmation of a correlation between the uPA inhibitory and anti-metastatic properties of the compounds will be sought, as will information relating the inhibitors' structural features to their efficacy in vivo. The eventual outcome of confirmation of the efficacy of the drugs tested as anti-metastatic agents is intended to be the identification of a therapeutic agent or agents which will be useful in all cases of diagnosed solid tumors in humans as prophylaxis against metastasis.